Literature DB >> 15917515

Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol.

Linda M Parsons1, Max Salfinger, Anne Clobridge, Jillian Dormandy, Lisa Mirabello, Valerie L Polletta, Ahmet Sanic, Oleg Sinyavskiy, Susan C Larsen, Jeffrey Driscoll, Genet Zickas, Harry W Taber.   

Abstract

In performing radiometric susceptibility testing on over 2,000 patient isolates of Mycobacterium tuberculosis during the past 6 years, we found that resistance to 7.5 microg/ml ethambutol (EMB) occurred only in isolates that are also resistant to 0.4 microg/ml isoniazid (INH). Using 157 selected isolates in the present study, we performed radiometric and agar proportion susceptibility tests and DNA sequencing of genetic regions associated with resistance to these two drugs. The goal was to study the occurrence of the common mutations associated with resistance to each drug and also to determine whether any particular INH-resistance-associated mutation occurred more often in combination with any particular EMB-resistance-associated mutation. In an analysis of 128 isolates resistant to 0.4 microg/ml INH, we found that a mutation at katG Ser315 was more common in isolates also resistant to 7.5 microg/ml EMB (61 of 67=91.0%) than in isolates either susceptible to EMB or resistant to 2.5 microg/ml EMB (39 of 60=65.0%). These observations suggest that INH-resistant strains with a mutation at katG Ser315 are more likely to acquire resistance to 7.5 microg/ml EMB than are isolates with INH-resistance-associated mutations at other sites. In addition, we found that 64 of 67 (95.5%) isolates resistant to 7.5 microg/ml EMB contained a mutation in either codon 306 or codon 406 of embB. Met306Val was the most common embB mutation, present in 52 (77.6%) of the 67 isolates. Most occurrences of this mutation (49 of 52=94.2%) were found in isolates that also contained the katG Ser315Thr mutation. Finally, sequencing this region of embB appears to be sufficiently sensitive for use as a rapid screening tool for detection of high-level resistance to EMB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917515      PMCID: PMC1140517          DOI: 10.1128/AAC.49.6.2218-2225.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 2.  The effect of drug resistance on the fitness of Mycobacterium tuberculosis.

Authors:  Ted Cohen; Ben Sommers; Megan Murray
Journal:  Lancet Infect Dis       Date:  2003-01       Impact factor: 25.071

3.  Persistence of a highly resistant strain of tuberculosis in New York City during 1990-1999.

Authors:  Sonal S Munsiff; Beth Nivin; Galit Sacajiu; Barun Mathema; Pablo Bifani; Barry N Kreiswirth
Journal:  J Infect Dis       Date:  2003-07-18       Impact factor: 5.226

4.  Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods.

Authors:  B Madison; B Robinson-Dunn; I George; W Gross; H Lipman; B Metchock; A Sloutsky; G Washabaugh; G Mazurek; J Ridderhof
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

5.  Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.

Authors:  G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

6.  Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998.

Authors:  A Laszlo; M Rahman; M Espinal; M Raviglione
Journal:  Int J Tuberc Lung Dis       Date:  2002-09       Impact factor: 2.373

Review 7.  Laboratory diagnostic aspects of drug resistant tuberculosis.

Authors:  Linda M Parsons; Akos Somoskövi; Richard Urbanczik; Max Salfinger
Journal:  Front Biosci       Date:  2004-09-01

Review 8.  Mechanisms of drug resistance in Mycobacterium tuberculosis.

Authors:  Mary Margaret Wade; Ying Zhang
Journal:  Front Biosci       Date:  2004-01-01

9.  Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis.

Authors:  Linda M Parsons; Roland Brosch; Stewart T Cole; Akos Somoskövi; Arthur Loder; Gisela Bretzel; Dick Van Soolingen; Yvonne M Hale; Max Salfinger
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

10.  Rapid drug-susceptibility testing of Mycobacterium tuberculosis.

Authors:  D E Snider; R C Good; J O Kilburn; L F Laskowski; R H Lusk; J J Marr; Z Reggiardo; G Middlebrook
Journal:  Am Rev Respir Dis       Date:  1981-04
View more
  30 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France.

Authors:  Florence Brossier; Wladimir Sougakoff; Christine Bernard; Matthieu Petrou; Karine Adeyema; Anne Pham; Diane Amy de la Breteque; Marine Vallet; Vincent Jarlier; Christophe Sola; Nicolas Veziris
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

4.  Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis.

Authors:  Wei-Lun Huang; Ting-Lin Chi; Mei-Hua Wu; Ruwen Jou
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

5.  Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates.

Authors:  Claudia Plinke; Sabine Rüsch-Gerdes; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo.

Authors:  Claudia Plinke; Kerstin Walter; Sahar Aly; Stefan Ehlers; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

7.  Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Authors:  Shashikant Srivastava; Sandirai Musuka; Carleton Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

8.  Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens.

Authors:  Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

9.  Association between embB Codon 306 Mutations, Phenotypic Resistance Profiles, and Genotypic Characterization in Clinical Mycobacterium tuberculosis Isolates from Hebei, China.

Authors:  Yanan Li; Yuling Wang; Zhi Zhang; Huixia Gao; Haibin Wang; Jinfeng Cao; Shumin Zhang; Yuzhen Liu; Jianhua Lu; Zungui Xu; Erhei Dai
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Single-nucleotide polymorphism in two representative multidrug-resistant Mycobacterium bovis isolates collected from patients in a Spanish hospital harboring a human infection outbreak.

Authors:  Beatriz Romero; Alicia Aranaz; Javier Bezos; Julio Alvarez; Lucía de Juan; Ana Mateos; Enrique Gómez-Mampaso; Lucas Domínguez
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.